Nurix Therapeutics is a biopharmaceutical company that focuses on the development and discovery of small molecule drugs.
Nurix Therapeutics has raised $250.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in October 2025.
Nurix Therapeutics's investors include General Atlantic, Wellington Management, Perceptive Advisors, Redmile Group, Foresite Capital.
Nurix Therapeutics is headquartered in San Francisco, United States.
Nurix Therapeutics is a biopharmaceutical company that focuses on the development and discovery of small molecule drugs.
Nurix Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Nurix Therapeutics — Funding & Investors." VCBacked, October 22, 2025, https://www.vcbacked.co/company/nurix-therapeutics. Accessed September 16, 2026.
VCBacked. (2025). Nurix Therapeutics — Funding & Investors. Retrieved September 16, 2026, from https://www.vcbacked.co/company/nurix-therapeutics
{{cite web |title=Nurix Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/nurix-therapeutics |website=VCBacked |access-date=September 16, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated